Green Light Committee application instructions

Overview

Management of drug-resistant tuberculosis (DR-TB) under programmatic conditions is a complex intervention in public health, not yet fully established in many countries. The treatment that does not meet international standards, however, risks amplifying and spreading multidrug-resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB) further. The global response to MDR-TB and XDR-TB, embedded in the Global Plan to Stop TB 2006-2015, has the target of achieving universal access to diagnosis and treatment of MDR-TB by 2015.

The WHO Guidelines For The Programmatic Management Of Drug Resistant Tuberculosis (herein after referred to as the WHO Guidelines)2 provide recommendations for appropriate management of DR-TB to control it, avoid generation of further drug resistance and taking into consideration community based / ambulatory and patient centered care. The Green Light Committee (GLC) was created by WHO and its partners in January 2000 with the objective to help programmes/ projects develop and implement strategies for the management of DR-TB.